RGS22
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| regulator of G protein signaling 22 | MIM:615650 | Ensembl:ENSG00000132554 | HGNC:HGNC:24499 | PA142671068 | 8q22.2 |
GO terms in RGS22
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IEA | GO:0009968 | negative regulation of signal transduction |
| BP | IEA | GO:0043547 | positive regulation of GTPase activity |
| CC | IEA | GO:0005634 | nucleus |
Gene expression in normal tissue: RGS22
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in RGS22
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-372790 | Signaling by GPCR |
| reactome | R-HSA-388396 | GPCR downstream signalling |
| reactome | R-HSA-418594 | G alpha (i) signalling events |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD779 | PRL-3 Inhibitor I | 2 |
| iGMDRD433 | Lexibulin | 3 |
| iGMDRD151 | CHM-1 | 1 |
| iGMDRD84 | Lovastatin acid | 3 |
| iGMDRD599 | Salermide | 3 |
| iGMDRD123 | Isoevodiamine | 5 |
| iGMDRD394 | BX-795 | 2 |
| iGMDRD132 | (-)-gallocatechin-3-O-gallate | 2 |
| iGMDRD945 | ML214 | 3 |
| iGMDRD446 | LY 2183240 | 3 |
| iGMDRD193 | Fqi1 | 5 |
| iGMDRD639 | YK 4-279 | 3 |
| iGMDRD316 | N9-Isopropyl-olomoucine | 2 |
| iGMDRD434 | BMS-536924 | 1 |
| iGMDRD77 | Itraconazole | 1 |
| iGMDRD318 | PAC-1 | 5 |
| iGMDRD138 | PX 12 | 2 |
| iGMDRD260 | FQI-2 | 1 |
| iGMDRD255 | SB225002 | 2 |
| iGMDRD60 | Quinoclamine | 2 |
| iGMDRD246 | NPC26 | 4 |
| iGMDRD64 | Parbendazole | 6 |
| iGMDRD505 | Pevonedistat | 2 |
| iGMDRD188 | Piperlongumine | 2 |
| iGMDRD398 | Sepantronium | 3 |
Gene in drug-gene network: Network Plot

Gene-drug targets distribution
Gene Structure: PDB
Models in RGS22

